Responses
Featured Posters: Poster Rounds with the Professors
AS04. Endometrial/Uterine corpus cancers
PR023/#503 Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability
Compose a Response to This Article
Other responses
No responses have been published for this article.